{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:23:21Z","timestamp":1787660601250,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.acvd.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:06:33Z","timestamp":1769875593000},"page":"566-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of mavacamten on left ventricular diastolic function and left atrial remodelling in obstructive hypertrophic cardiomyopathy"],"prefix":"10.1016","volume":"119","author":[{"given":"Nicolas","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7951-2048","authenticated-orcid":false,"given":"Claire","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Idini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoire","family":"Stolpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-9983","authenticated-orcid":false,"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.acvd.2026.01.006_bib0120","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2026.01.006_bib0125","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000001250","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"issue":"37","key":"10.1016\/j.acvd.2026.01.006_bib0130","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC Guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"10253","key":"10.1016\/j.acvd.2026.01.006_bib0135","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM)","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.acvd.2026.01.006_bib0140","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"6\u20137","key":"10.1016\/j.acvd.2026.01.006_bib0145","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.acvd.2024.04.001","article-title":"Target population for a selective cardiac myosin inhibitor in hypertrophic obstructive cardiomyopathy: Real-life estimation from the French register of hypertrophic cardiomyopathy (REMY)","volume":"117","author":"Parodi","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.acvd.2026.01.006_bib0150","doi-asserted-by":"crossref","first-page":"e014986","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"issue":"7","key":"10.1016\/j.acvd.2026.01.006_bib0155","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/echo.13857","article-title":"E\/e\u2032 ratio and left atrial area are predictors of atrial fibrillation in patients with hypertrophic cardiomyopathy","volume":"35","author":"Costabel","year":"2018","journal-title":"Echocardiography"},{"issue":"12","key":"10.1016\/j.acvd.2026.01.006_bib0160","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1111\/echo.14539","article-title":"Prognostic significance of left ventricular end-diastolic pressure using E\/E\u2032 in patients with hypertrophic cardiomyopathy","volume":"36","author":"Badran","year":"2019","journal-title":"Echocardiography"},{"issue":"2","key":"10.1016\/j.acvd.2026.01.006_bib0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40119-025-00409-5","article-title":"Effect of mavacamten on echocardiographic features in Chinese patients with obstructive hypertrophic cardiomyopathy: results from the EXPLORER-CN study","volume":"14","author":"Tian","year":"2025","journal-title":"Cardiol Ther"},{"issue":"4","key":"10.1016\/j.acvd.2026.01.006_bib0170","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ihj.2025.05.011","article-title":"The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients: a systematic review and meta-analysis","volume":"77","author":"Otmani","year":"2025","journal-title":"Indian Heart J"},{"issue":"24","key":"10.1016\/j.acvd.2026.01.006_bib0175","first-page":"2434","article-title":"Echocardiographic changes with mavacamten in nonobstructive hypertrophic cardiomyopathy: exploratory insights from the ODYSSEY-HCM trial","volume":"86","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"Suppl. 1","key":"10.1016\/j.acvd.2026.01.006_bib0180","article-title":"Effects of mavacamten on left atrial function in hypertrophic obstructive cardiomyopathy","volume":"26","author":"Ozbay","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.acvd.2026.01.006_bib0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12968-021-00793-6","article-title":"Incremental value of left atrial booster and reservoir strain in predicting atrial fibrillation in patients with hypertrophic cardiomyopathy: a cardiovascular magnetic resonance study","volume":"23","author":"Raman","year":"2021","journal-title":"J Cardiovasc Magn Reson"},{"issue":"25","key":"10.1016\/j.acvd.2026.01.006_bib0190","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.acvd.2026.01.006_bib0195","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ehjci\/jeab001","article-title":"Impact of left atrial strain mechanics on exercise intolerance and need for septal reduction therapy in hypertrophic cardiomyopathy","volume":"23","author":"Saijo","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.acvd.2026.01.006_bib0200","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"10.1016\/j.acvd.2026.01.006_bib0205","first-page":"987","article-title":"Effect of aficamten compared with metoprolol on echocardiographic measures in symptomatic obstructive hypertrophic cardiomyopathy: results from the MAPLE-HCM trial","volume":"85","author":"Hegde","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.acvd.2026.01.006_bib0210","first-page":"2213","article-title":"Impact of aficamten on echocardiographic cardiac structure and diastolic function in symptomatic obstructive hypertrophic cardiomyopathy","volume":"84","author":"Hegde","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.acvd.2026.01.006_bib0215","doi-asserted-by":"crossref","first-page":"e044537","DOI":"10.1161\/JAHA.125.044537","article-title":"Real-world observations in obstructive hypertrophic cardiomyopathy patients treated with mavacamten: evidence of favorable disease modification","volume":"14","author":"Desai","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2026.01.006_bib0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.amjcard.2025.01.032","article-title":"Real-world assessment of mavacamten's impact on LV systolic and diastolic function in obstructive hypertrophic cardiomyopathy: one-year single-center study","volume":"242","author":"Abood","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2026.01.006_bib0225","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM","volume":"151","author":"Owens","year":"2025","journal-title":"Circulation"},{"issue":"6\u20137","key":"10.1016\/j.acvd.2026.01.006_bib0230","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.acvd.2024.03.003","article-title":"Evaluation of new predictive scores for sudden cardiac death in childhood hypertrophic cardiomyopathy in a French cohort","volume":"117","author":"Fontanges","year":"2024","journal-title":"Arch Cardiovasc Dis"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213626000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213626000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:38:20Z","timestamp":1787657900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213626000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":23,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1875213626000173"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2026.01.006","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of mavacamten on left ventricular diastolic function and left atrial remodelling in obstructive hypertrophic cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}